問卷

TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Dermatology

National Taiwan University Hospital Yunlin Branch  (在職)

Division of Dermatology

更新時間:2023-09-19

王鼎舜
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

15Cases

2020-01-09 - 2026-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-15 - 2020-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-10-01 - 2020-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-04-01 - 2020-08-24

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-08-31 - 2025-11-11

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-06-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-12-13 - 2020-12-09

Phase III

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    ABT-494 (Upadacitinib)

Participate Sites
4Sites

Terminated4Sites

2019-12-01 - 2022-12-31

Phase IV

A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Have a Suboptimal Response to Secukinumab or Ixekizumab and Are Switched to Risankizumab
  • Condition/Disease

    Moderate to Severe Plaque Psoriasis

  • Test Drug

    Risankizumab Risankizumab

Participate Sites
4Sites

Recruiting4Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)
  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites

2019-07-10 - 2020-02-12

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    REGN3500 and REGN668 (Dupilumab)

Participate Sites
4Sites

Terminated4Sites

1 2